DIAGNOS Announces Partnership in Saudi Arabia with Magrabi Hospitals and Centers to Screen Diabetic Patients
January 14 2021 - 8:30AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK),
(OTCQB: DGNOF), a leader in early detection of critical health
issues through the use of Artificial Intelligence (AI), is pleased
to announce the opening of five screening clinics at various
locations of Magrabi Hospital & Centers (“Magrabi”) located in
Riyadh, with the help of its Saudi business partner, Kanhoor
Medical Co. (“Kanhoor”).
Magrabi is one of the largest eye care networks
in the world, providing eye care to more than 1 million patients
and performing more than 100,000 sight-preserving surgeries
annually. Magrabi operates in 30 locations in the Kingdom of Saudi
Arabia, United Arab Emirates, Qatar, Saltanat of Oman, Yemen and
Egypt.
Magrabi is launching DIAGNOS’ AI assisted
screening project to increase the availability of this service to
its large number of diabetic patients. Being more strategically
located near the patient base, CARA can offer its service to
dramatically increase its volume of medical tests in a short period
of time. Following the prompt execution of this project, the plan
is to extend the screening to all Magrabi hospitals in the Kingdom,
Middle East and Africa.
“This project is the result of many months of
detailed work with Magrabi and 2 field trials. This commercial
project is establishing the foundation of a partnership between
Magrabi, Kanhoor and DIAGNOS to deploy in the remaining 22 clinics
in Saudi Arabia in second half of 2021 and abroad in other Middle
Eastern and African locations.” said Yves-Stéphane
Couture, Vice-President of Sales for DIAGNOS.
About MagrabiFounded in 1955, Magrabi Hospitals & Centers
has evolved from a simple eye hospital in Jeddah, the first private
specialized facility in the Middle East and Africa to a network of
35 hospitals. Now, Magrabi has become the largest eye care network
in the world, providing eye care to more than 1,000,000 patients
and performing more than 100,000 sight-preserving surgeries
annually. Magrabi operates in 6 countries: Kingdom of Saudi Arabia,
United Arab Emirates, Qatar, Saltanat of Oman, Yemen, and
Egypt.
About Kanhoor Medical CoAl Kanhoor is focused on selling
telemedicine and AI assisted application in KSA. Al Kanhoor is
providing technology for remote patient observation and marketing
DIAGNOS’ products in KSA and beyond. Al Kanhoor is a sister company
of HAJZTELECOM “HTC” Technology & Telecom solutions provider
and contractor to Saudi Telecom - STC- contractor since 1997.
About DIAGNOSDIAGNOS is a public Canadian
company dedicated to early detection of health problems based on
its FLAIRE artificial intelligence (AI) platform. The use of the
FLAIRE platform allows rapidly modifying and developing its
applications such as CARA (Computer Assisted Retina Analysis).
CARA's artificial intelligence-based image enhancement algorithms
provide sharper, clearer, and easier-to-analyze traditional retinal
images that can be analyzed̀. CARA is a cost-effective tool for
real-time screening in a large number of patients. CARA has been
approved by a number of regulators, including Canada (Health
Canada), the United States (FDA), Mexico (COFEPRIS), Europe (EC)
and the Saudi FDA.
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024